News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
22,020 Results
Type
Article (836)
Press Release (21184)
Section
Business (11552)
Career Advice (15)
Deals (1406)
Drug Delivery (2)
Drug Development (1653)
FDA (313)
Job Trends (473)
News (14238)
Policy (512)
Tag
Academia (25)
Accelerated approval (1)
Allergies (1)
Alliances (594)
ALS (6)
Alzheimer's disease (22)
Antibody-drug conjugate (ADC) (11)
Approvals (334)
Artificial intelligence (1)
Autoimmune disease (8)
Bankruptcy (6)
Best Places to Work (401)
Biosimilars (4)
Biotechnology (1)
Bladder cancer (6)
Brain cancer (1)
Breast cancer (12)
Cancer (130)
Cardiovascular disease (21)
Career advice (12)
CAR-T (6)
Cell therapy (13)
Cervical cancer (1)
Clinical research (1612)
Collaboration (21)
Compensation (17)
COVID-19 (32)
CRISPR (1)
C-suite (6)
Cystic fibrosis (6)
Data (221)
Depression (1)
Dermatology (5)
Diabetes (21)
Diagnostics (200)
Digital health (3)
Drug discovery (2)
Drug pricing (3)
Duchenne muscular dystrophy (3)
Earnings (11607)
Editorial (2)
Events (1980)
Executive appointments (2)
FDA (494)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (14)
Gene editing (2)
Gene therapy (11)
GLP-1 (47)
Government (30)
Guidances (117)
Healthcare (514)
IgA nephropathy (4)
Immunology and inflammation (7)
Indications (9)
Infectious disease (38)
Inflammatory bowel disease (4)
Intellectual property (5)
Interviews (4)
IPO (1109)
Job creations (87)
Job search strategy (11)
Kidney cancer (1)
Labor market (6)
Layoffs (10)
Leadership (1)
Legal (108)
Liver cancer (1)
Lung cancer (26)
Lymphoma (10)
Manufacturing (9)
MASH (13)
Medical device (533)
Medtech (537)
Mergers & acquisitions (312)
Metabolic disorders (73)
mRNA (2)
Multiple sclerosis (8)
NASH (1)
Neurodegenerative disease (7)
Neuropsychiatric disorders (7)
Neuroscience (58)
NextGen: Class of 2026 (90)
Non-profit (31)
Now hiring (1)
Obesity (34)
Opinion (3)
Ovarian cancer (4)
Pain (3)
Pancreatic cancer (8)
Parkinson's disease (8)
Patents (1)
Patient recruitment (4)
Peanut (1)
People (623)
Pharmacy benefit managers (1)
Phase 1 (373)
Phase 2 (650)
Phase 3 (650)
Pipeline (649)
Policy (2)
Postmarket research (73)
Preclinical (121)
Prostate cancer (12)
Radiopharmaceuticals (12)
Rare diseases (23)
Real estate (63)
Regulatory (462)
Reports (4)
Research institute (27)
Resumes & cover letters (5)
Rett syndrome (2)
RSV (3)
Schizophrenia (7)
Series A (2)
Series B (1)
Sickle cell disease (4)
Special edition (1)
Spinal muscular atrophy (2)
Startups (27)
Supply chain (1)
Tariffs (1)
Vaccines (14)
Weight loss (37)
Women's health (6)
Date
Last 7 days (28)
Last 30 days (122)
Last 365 days (1268)
2026 (362)
2025 (1221)
2024 (1390)
2023 (1555)
2022 (1650)
2021 (1733)
2020 (1491)
2019 (1013)
2018 (876)
2017 (680)
2016 (384)
2015 (643)
2014 (5839)
2013 (280)
2012 (269)
2011 (349)
2010 (377)
Location
Africa (8)
Alabama (2)
Arizona (10)
Arkansas (1)
Asia (1234)
Australia (119)
California (460)
Canada (121)
China (32)
Colorado (29)
Connecticut (24)
Delaware (19)
Europe (3025)
Florida (71)
Georgia (25)
Illinois (51)
India (3)
Indiana (39)
Japan (19)
Kansas (1)
Kentucky (2)
Louisiana (8)
Maine (6)
Maryland (55)
Massachusetts (293)
Michigan (16)
Minnesota (37)
Missouri (4)
Nevada (2)
New Hampshire (7)
New Jersey (167)
New York (136)
North Carolina (64)
Northern California (242)
Ohio (14)
Pennsylvania (112)
South America (30)
Southern California (182)
Tennessee (8)
Texas (53)
United States (1746)
Utah (22)
Virginia (2)
Washington D.C. (1)
Washington State (53)
Wisconsin (5)
22,020 Results for "147".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EOM Pharmaceutical Holdings Reports Promising Preclinical Results and Provides an Update on EOM613 and EOM147
January 8, 2026
·
7 min read
Press Releases
BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and Additional $3.8 Million in Debt Reduction
September 22, 2025
·
3 min read
Press Releases
Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer
September 9, 2025
·
6 min read
Business
Illumina Reports $1.47B ‘Goodwill’ Impairment Charge After Grail Spinoff
Following the recently completed spinoff of cancer detection company Grail, sequencing giant Illumina said Thursday it expects to absorb a $1.47 billion goodwill impairment charge.
June 28, 2024
·
2 min read
·
Tristan Manalac
FDA
Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147
Abdera Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ABD-147.
May 23, 2024
·
5 min read
Press Releases
Abdera Therapeutics to Present Early Pharmacokinetics, Dosimetry and Safety Data from Ongoing Phase 1 Trial of ABD-147 at the IASLC 2025 World Conference on Lung Cancer and Participate in Upcoming Investor Conferences
August 27, 2025
·
3 min read
FDA
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
Abdera Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABD-147 for the treatment of patients with extensive stage small cell lung cancer (ES-SCLC) who have progressed on or after platinum-based chemotherapy.
June 27, 2024
·
4 min read
Press Releases
BioHarvest Sciences Reports Third Quarter 2025 Financial Results
Strong VINIA Momentum and New CDMO Win Delivers 39% Year-Over-Year GrowthCompany Fortifies Balance Sheet with Recent $19.9 Million Instiutional Equity Raise Following $14.7 Million Strengthening of Balance Sheet via Accelerated Warrant Exercises and Debt-to-Equity Conversions in September
November 13, 2025
·
14 min read
Press Releases
Noema Pharma extends Series B financing round, closing at CHF 130 Million ($147 Million)
December 11, 2024
·
3 min read
Drug Development
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.
April 1, 2024
·
7 min read
1 of 2,202
Next
